Sponsored by Lilly

CDK4/6 Inhibitors in Early Breast Cancer

High-Risk, Node-Positive, HR-Positive/HER2-Negative Early Breast Cancer
Stream the Case-Based Exchange Webinar: “High-Risk, Node-Positive, HR-Positive/HER2-Negative Early Breast Cancer” to hear perspectives on markers of high-risk disease and practical treatment approaches from Neil Iyengar, MD, and Annalise Labatut, PharmD, BCOP, of the Winship Cancer Institute of Emory University. Topics include the role of the CDK4/6 inhibitor in adjuvant treatment. Watch Now ›


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: